First patient recruited for IDRIS trial
28 August 2017
This month has seen a CTC study investigating the treatment of plasmacytoma recruit its first patient.

IDRIS, a phase III trial funded by Cancer Research UK, is looking at additional treatment for solitary bone plasmacytoma (that is, a tumour formed by a collection of blood plasma cells at a single point in the skeleton) beyond the standard course of radiotherapy. Researchers think giving a patient immunotherapy (in the form of lenalidomide) and a steroid called dexamethasone might prevent the plasmacytoma from recurring or developing into myeloma (a type of cancer which starts in the bone marrow).

The study also aims to find out more about the side effects of these two additional drugs, as well as how their inclusion in treatment affects a patient’s quality of life.

Senior trial coordinator Ellice Marwood commented: ‘We are looking forward to opening the trial in more hospitals and recruiting more patients to answer the important research questions and help future patients diagnosed with solitary bone plasmacytoma.’ 

More details on the trial can be found here.
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us